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Introduction
Parapneumonic effusions and empyemas present difficult diagnostic and therapeutic challenges because of their highly variable clinical presentation and response to therapy [1] [2] . It is estimated that at least 40% of hospitalized patients with pneumonia develop a parapneumonic effusion, which is associated with an increased morbidity and a mortality of 15% [1] [2] [3] . There is considerable variation in the clinical course of patients with parapneumonic effusions. Appropriate therapy varies depending on clinical circumstances and includes antibiotic therapy alone for uncomplicated effusions, chest tube or surgical drainage for complicated effusions, and surgical drainage for established, organized empyemas.
Recommendations exist to instill the fibrinolytic drugs, streptokinase or urokinase, into the pleural space of patients undergoing chest tube drainage to lyse fibrinous adhesions, enhance pleural fluid drainage and reduce the need for surgical drainage and mechanical debridement [3] . Existing studies, however, conflict in demonstrated efficacy of these approaches. More recent reports have increased interest in the intrapleural use of novel drugs, singly or in combination with fibrinolytic drugs, that decrease the viscosity of empyema pus to promote drainage 1 or interfere with the formation of intrapleural fibrous bands [1] [2] . Limited data exist regarding the utility of these agents.
This review will discuss the use of fibrinolytic agents based on existing data and describe the potential utility of more novel approaches to the non-surgical management of PPE and PE. 
Methods
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Pathophysiology and Classification
The progression of an uncomplicated PPE to an organized PE represents an inflammatory continuum from a small, free-flowing, non-infected pleural effusion to a large volume of frank pus, which may be multi-loculated with thick visceral pleural peels that prevent the underlying lung from expanding to the chest wall after pleural fluid drainage ("trapped lung").
During the early stages of pneumonia, pleural membranes respond to pulmonary pathogens with a vigorous inflammatory response that promotes the formation of pleural fluid, which is exudative in nature with increased concentrations of leukocytes and proteins. Initially, the pleural fluid has a normal glucose (> 60 mg/dL) and pH (>7. 
TREATMENT OF PPE and PE
Pharmacology of Fibrinolytics
Streptokinase is a non-enzymatic protein produced by the Lancefield group C strain of β-hemolytic streptococci (exotoxin), which activates the fibrinolytic system indirectly 
Contraindications:
Other than an allergic history to these agents, contraindications for intrapleural administration of fibrinolytics are not clearly established and derive largely from anecdotal clinical experience (Table 2) [16].
A c c e p t e d m a n u s c r i p t
A c c e p t e d m a n u s c r i p t The value of medical thoracoscopy as compared with fibrinolytic therapy or VATSinitiated drainage for the management of PPE has not been evaluated in clinical trials.
Comparison of streptokinase versus VATS
A c c e p t e d m a n u s c r i p t A c c e p t e d m a n u s c r i p t
Medical thoracoscopy has potential benefits as compared with VATS in that medical thoracoscopy can be performed under local anesthesia or conscious sedation in an endoscopy suite at a lower expense [72] .
Future investigation
Streptokinase and urokinase represent less than ideal drugs for managing PPE because they have short half-lives and require repeated instillations, lack specificity for fibrin, present a potential for systemic absorption, and do not decrease the viscosity of intrapleural pus to enhance chest tube drainage. Other drugs are undergoing evaluation to identify a more effective drug or combination of drugs for patients with PPE and PE Tissue plasminogen activator (Alteplase®, t-PA)
Tissue plasminogen activator provides fibrinolytic activity without the antigenicity of streptokinase. Only two case reports and a single retrospective study in pediatric age groups exist to support the utility of t-PA for managing PPE [77] [78] [79] . The retrospective 
Conclusions and Recommendations
No high-grade evidence from large-scale, RCT support the utility of fibrinolytic therapy in the management of patients with PPE or PE. Consequently, fibrinolytic therapy should not be used routinely for all patients with PPE who require chest tube drainage. 
